Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim

Koichiro Wasano, Taiji Kawasaki, Yoshihiko Hiraga, Sayuri Yamamoto, Shuta Tomisato, Yosuke Hashimoto, Kaoru Ogawa

Research output: Contribution to journalArticle

Abstract

The TPF protocol composed of docetaxel, cisplatine and 5-fluorouracil, is the most commonly used chemotherapy regimen for the treatment of head and neck cancer. Recently, the importance of maintaining a relative dose-intensity (RDI) has been shown. Therefore, the treatment and prevention of febrile neutropenia, which can reduce the RDI of the TPF protocol, are important. Here, we compare patient outcomes before and after the introduction of pegfilgrastim for primary prophylaxis. The first group is consisted of 60 patients (88 chemotherapy courses) treated between January 2011 and October 2014 who did not receive prophylaxis. The second group consisted of 14 patients (20 chemotherapy courses) treated between November 2014 and July 2016 using pegfilgrastim. We examined the frequency of neutropenia (grade 3 and 4), febrile neutropenia (FN) and treatment-related death, the amount of granulocyte-colony stimulating factor (G-CSF) used, the cost for FN treatment and the hospitalization period. In the first group, there were 74 neutropenia events, 34 cases of FN and 2 treatment-related deaths; the average hospitalization period was 18.5 days. In the second group, there were 74 neutropenia events, 34 case of FN, and 0 treatment-related death; the average hospitalization period was 18.5 days. The frequency of adverse events, the amount of G-CSF used, the cost for FN and the hospitalization period were all significantly reduced by the introduction of pegfilgrastim. In conclusion, the administration of pegfilgrastim for the primary prophylaxis of FN was effective when included in the TPF protocol for the treatment of head and neck cancer.

Original languageEnglish
Pages (from-to)287-293
Number of pages7
JournalPractica Oto-Rhino-Laryngologica
Volume110
Issue number4
Publication statusPublished - 2017

Fingerprint

docetaxel
Febrile Neutropenia
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Hospitalization
Neutropenia
Granulocyte Colony-Stimulating Factor
Drug Therapy
Therapeutics
Costs and Cost Analysis
TPF protocol
pegfilgrastim

Keywords

  • Febrile neutropenia
  • Granulocyte-colony stimulating factor
  • Head and neck cancer
  • Primary prophylaxis
  • Relative dose-intensity

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim. / Wasano, Koichiro; Kawasaki, Taiji; Hiraga, Yoshihiko; Yamamoto, Sayuri; Tomisato, Shuta; Hashimoto, Yosuke; Ogawa, Kaoru.

In: Practica Oto-Rhino-Laryngologica, Vol. 110, No. 4, 2017, p. 287-293.

Research output: Contribution to journalArticle

Wasano, Koichiro ; Kawasaki, Taiji ; Hiraga, Yoshihiko ; Yamamoto, Sayuri ; Tomisato, Shuta ; Hashimoto, Yosuke ; Ogawa, Kaoru. / Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim. In: Practica Oto-Rhino-Laryngologica. 2017 ; Vol. 110, No. 4. pp. 287-293.
@article{bc20dfd248124d0c817990504133b40a,
title = "Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim",
abstract = "The TPF protocol composed of docetaxel, cisplatine and 5-fluorouracil, is the most commonly used chemotherapy regimen for the treatment of head and neck cancer. Recently, the importance of maintaining a relative dose-intensity (RDI) has been shown. Therefore, the treatment and prevention of febrile neutropenia, which can reduce the RDI of the TPF protocol, are important. Here, we compare patient outcomes before and after the introduction of pegfilgrastim for primary prophylaxis. The first group is consisted of 60 patients (88 chemotherapy courses) treated between January 2011 and October 2014 who did not receive prophylaxis. The second group consisted of 14 patients (20 chemotherapy courses) treated between November 2014 and July 2016 using pegfilgrastim. We examined the frequency of neutropenia (grade 3 and 4), febrile neutropenia (FN) and treatment-related death, the amount of granulocyte-colony stimulating factor (G-CSF) used, the cost for FN treatment and the hospitalization period. In the first group, there were 74 neutropenia events, 34 cases of FN and 2 treatment-related deaths; the average hospitalization period was 18.5 days. In the second group, there were 74 neutropenia events, 34 case of FN, and 0 treatment-related death; the average hospitalization period was 18.5 days. The frequency of adverse events, the amount of G-CSF used, the cost for FN and the hospitalization period were all significantly reduced by the introduction of pegfilgrastim. In conclusion, the administration of pegfilgrastim for the primary prophylaxis of FN was effective when included in the TPF protocol for the treatment of head and neck cancer.",
keywords = "Febrile neutropenia, Granulocyte-colony stimulating factor, Head and neck cancer, Primary prophylaxis, Relative dose-intensity",
author = "Koichiro Wasano and Taiji Kawasaki and Yoshihiko Hiraga and Sayuri Yamamoto and Shuta Tomisato and Yosuke Hashimoto and Kaoru Ogawa",
year = "2017",
language = "English",
volume = "110",
pages = "287--293",
journal = "Practica Oto-Rhino-Laryngologica",
issn = "0032-6313",
publisher = "Society of Practical Otolaryngology",
number = "4",

}

TY - JOUR

T1 - Febrile neutropenia in patient with head and neck cancer treated with docetaxel, cisplatin and 5-fluorouracil (TPF protocol) - A comparison before and after the introduction of pegfilgrastim

AU - Wasano, Koichiro

AU - Kawasaki, Taiji

AU - Hiraga, Yoshihiko

AU - Yamamoto, Sayuri

AU - Tomisato, Shuta

AU - Hashimoto, Yosuke

AU - Ogawa, Kaoru

PY - 2017

Y1 - 2017

N2 - The TPF protocol composed of docetaxel, cisplatine and 5-fluorouracil, is the most commonly used chemotherapy regimen for the treatment of head and neck cancer. Recently, the importance of maintaining a relative dose-intensity (RDI) has been shown. Therefore, the treatment and prevention of febrile neutropenia, which can reduce the RDI of the TPF protocol, are important. Here, we compare patient outcomes before and after the introduction of pegfilgrastim for primary prophylaxis. The first group is consisted of 60 patients (88 chemotherapy courses) treated between January 2011 and October 2014 who did not receive prophylaxis. The second group consisted of 14 patients (20 chemotherapy courses) treated between November 2014 and July 2016 using pegfilgrastim. We examined the frequency of neutropenia (grade 3 and 4), febrile neutropenia (FN) and treatment-related death, the amount of granulocyte-colony stimulating factor (G-CSF) used, the cost for FN treatment and the hospitalization period. In the first group, there were 74 neutropenia events, 34 cases of FN and 2 treatment-related deaths; the average hospitalization period was 18.5 days. In the second group, there were 74 neutropenia events, 34 case of FN, and 0 treatment-related death; the average hospitalization period was 18.5 days. The frequency of adverse events, the amount of G-CSF used, the cost for FN and the hospitalization period were all significantly reduced by the introduction of pegfilgrastim. In conclusion, the administration of pegfilgrastim for the primary prophylaxis of FN was effective when included in the TPF protocol for the treatment of head and neck cancer.

AB - The TPF protocol composed of docetaxel, cisplatine and 5-fluorouracil, is the most commonly used chemotherapy regimen for the treatment of head and neck cancer. Recently, the importance of maintaining a relative dose-intensity (RDI) has been shown. Therefore, the treatment and prevention of febrile neutropenia, which can reduce the RDI of the TPF protocol, are important. Here, we compare patient outcomes before and after the introduction of pegfilgrastim for primary prophylaxis. The first group is consisted of 60 patients (88 chemotherapy courses) treated between January 2011 and October 2014 who did not receive prophylaxis. The second group consisted of 14 patients (20 chemotherapy courses) treated between November 2014 and July 2016 using pegfilgrastim. We examined the frequency of neutropenia (grade 3 and 4), febrile neutropenia (FN) and treatment-related death, the amount of granulocyte-colony stimulating factor (G-CSF) used, the cost for FN treatment and the hospitalization period. In the first group, there were 74 neutropenia events, 34 cases of FN and 2 treatment-related deaths; the average hospitalization period was 18.5 days. In the second group, there were 74 neutropenia events, 34 case of FN, and 0 treatment-related death; the average hospitalization period was 18.5 days. The frequency of adverse events, the amount of G-CSF used, the cost for FN and the hospitalization period were all significantly reduced by the introduction of pegfilgrastim. In conclusion, the administration of pegfilgrastim for the primary prophylaxis of FN was effective when included in the TPF protocol for the treatment of head and neck cancer.

KW - Febrile neutropenia

KW - Granulocyte-colony stimulating factor

KW - Head and neck cancer

KW - Primary prophylaxis

KW - Relative dose-intensity

UR - http://www.scopus.com/inward/record.url?scp=85018482060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018482060&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 287

EP - 293

JO - Practica Oto-Rhino-Laryngologica

JF - Practica Oto-Rhino-Laryngologica

SN - 0032-6313

IS - 4

ER -